![Christopher Haqq](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 365 863 $ au 31/05/2026
Christopher M.
Haqq currently works at Elicio Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2019.
Dr. Haqq also formerly worked at Consonance-HFW Acquisition Corp., as Independent Director from 2020 to 2021, Amgen, Inc., as Manager-Early Development Oncology Group, Cougar Biotechnology, Inc., as Vice President-Clinical Research & Development from 2007 to 2009, The University of California, San Francisco, as Assistant Professor, Janssen Oncology, Inc., as Vice President-Clinical Research & Development from 2007 to 2011, Atara Biotherapeutics, Inc., as Chief Scientific Officer, Executive VP-R&D from 2012 to 2019, and Elicio Therapeutics, Inc. (United States), as Chief Medical Officer & Executive Vice President from 2019 to 2023.
Dr. Haqq received his undergraduate degree from Stanford University and doctorate degree from Harvard Medical School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC 0,17 % | 09/04/2026 | 31 981 ( 0,17 % ) | 365 863 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/10/2019 |
| Sociétés | Poste | Fin |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Directeur Technique/Scientifique/R&D | 01/06/2023 |
| SURROZEN, INC. | Directeur/Membre du Conseil | 01/04/2021 |
| ATARA BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 25/10/2019 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Directeur Technique/Scientifique/R&D | 01/09/2011 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Directeur Technique/Scientifique/R&D | 13/07/2009 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Elicio Therapeutics, Inc.
 Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
